Osteopontin: A potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses

Satoshi Konno, Nobuyuki Hizawa, Masaharu Nishimura, Shau Ku Huang

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.

Original languageEnglish
Pages (from-to)355-359
Number of pages5
JournalAllergology International
Volume55
Issue number4
DOIs
Publication statusPublished - Jan 1 2006
Externally publishedYes

Keywords

  • Biomarker
  • Clustering
  • Mechanism
  • Microarray
  • Osteopontin (OPN)
  • Venom immunotherapy (VIT)

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Osteopontin: A potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses'. Together they form a unique fingerprint.

  • Cite this